Cleared Traditional

K974208 - TYTRON C-3000 (FDA 510(k) Clearance)

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K974208 · Titronics Research & Development Co. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1998
Decision
85d
Days
Class 2
Risk

K974208 is an FDA 510(k) clearance for the TYTRON C-3000. Classified as Device, Temperature Measurement, Direct Contact, Powered (product code HCS), Class II - Special Controls.

Submitted by Titronics Research & Development Co. (Oxford, US). The FDA issued a Cleared decision on February 3, 1998 after a review of 85 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1570 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Titronics Research & Development Co. devices

Submission Details

510(k) Number K974208 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 10, 1997
Decision Date February 03, 1998
Days to Decision 85 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
63d faster than avg
Panel avg: 148d · This submission: 85d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HCS Device, Temperature Measurement, Direct Contact, Powered
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.